Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2018

22.10.2018 | Original Article

Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer

verfasst von: Robert J. Mayer, Howard S. Hochster, Steven J. Cohen, Robert Winkler, Lukas Makris, Axel Grothey

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age. Here, we report the safety and tolerability profile of FTD/TPI from an expanded-access program (EAP) in the US patients with mCRC whose disease has progressed on the standard therapies.

Methods

A total of 549 patients (≥ 18 years) with histologically confirmed mCRC following two or more regimens of standard therapy and an Eastern Cooperative Oncology Group performance status of 0 or 1 participated in this open-label EAP. During the 28-day treatment cycle, patients took FTD/TPI 35 mg/m2 twice daily for 5 days followed by 2 days of rest for 2 weeks, with a 14-day rest period. Data were collected for therapy duration, treatment discontinuation, and adverse events. Age-based post hoc analysis was performed to determine the safety of FTD/TPI in elderly (≥ 65 years) versus younger (< 65 years) patients.

Results

FTD/TPI-treated patients in this EAP had a similar therapy duration and time to treatment discontinuation to those in the RECOURSE trial. The safety profile in elderly patients was consistent with that in younger patients, with no unexpected safety concerns.

Conclusions

This USA-based, open-label EAP has confirmed a similar safety and tolerability profile for FTD/TPI to that observed in the RECOURSE trial. Furthermore, FTD/TPI is well tolerated and can be considered as a treatment option in elderly patients with mCRC.

Trial registration

NCT02286492.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRef Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRef
3.
Zurück zum Zitat Heidelberger C, Ansfield FJ (1963) Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 23:1226–1243PubMed Heidelberger C, Ansfield FJ (1963) Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 23:1226–1243PubMed
4.
Zurück zum Zitat Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S et al (2015) Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther 14(4):1004–1013CrossRef Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S et al (2015) Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther 14(4):1004–1013CrossRef
5.
Zurück zum Zitat Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59(10):1227–1236CrossRef Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59(10):1227–1236CrossRef
6.
Zurück zum Zitat Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25(3):571–578PubMed Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25(3):571–578PubMed
7.
Zurück zum Zitat Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A et al (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383–1390CrossRef Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A et al (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383–1390CrossRef
8.
Zurück zum Zitat Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A et al (2008) Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794–799CrossRef Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A et al (2008) Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794–799CrossRef
9.
Zurück zum Zitat Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K et al (2008) Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445–454CrossRef Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K et al (2008) Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445–454CrossRef
10.
Zurück zum Zitat Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429–434CrossRef Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429–434CrossRef
11.
Zurück zum Zitat Green MC, Pusztai L, Theriault RL, Adinin RB, Hofweber M, Fukushima M et al (2006) Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 24(18 Suppl):10576 (abstract no. 10576) Green MC, Pusztai L, Theriault RL, Adinin RB, Hofweber M, Fukushima M et al (2006) Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 24(18 Suppl):10576 (abstract no. 10576)
12.
Zurück zum Zitat Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993–1001CrossRef Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993–1001CrossRef
13.
Zurück zum Zitat Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919CrossRef Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919CrossRef
15.
Zurück zum Zitat Mayer RJ, Grothey A, Hochster HS, Cohen SJ, Vukovic VM, Makris L (2017) An open-label expanded-access study of trifluridine/tipiracil for metastatic colorectal cancer. J Clin Oncol 35(15 Suppl):3559 (abstract no. 3559)CrossRef Mayer RJ, Grothey A, Hochster HS, Cohen SJ, Vukovic VM, Makris L (2017) An open-label expanded-access study of trifluridine/tipiracil for metastatic colorectal cancer. J Clin Oncol 35(15 Suppl):3559 (abstract no. 3559)CrossRef
16.
Zurück zum Zitat Mayer RJ, Hochster HS, Cohen SJ, Vukovic VM, Makris L, Grothey A (2017) An open-label expanded-access study of trifluridine/tipiracil for metastatic colorectal cancer. In: Poster 3559 presented at American Society of Clinical Oncology Annual Meeting Mayer RJ, Hochster HS, Cohen SJ, Vukovic VM, Makris L, Grothey A (2017) An open-label expanded-access study of trifluridine/tipiracil for metastatic colorectal cancer. In: Poster 3559 presented at American Society of Clinical Oncology Annual Meeting
17.
Zurück zum Zitat Garcia-Alfonso P, Ruiz A, Carrato A, Viéitez JM, Gravalos C, Pericay C (2017) Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data. J Clin Oncol 35 (Suppl):e15019 (abstract no. e15019)CrossRef Garcia-Alfonso P, Ruiz A, Carrato A, Viéitez JM, Gravalos C, Pericay C (2017) Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data. J Clin Oncol 35 (Suppl):e15019 (abstract no. e15019)CrossRef
18.
Zurück zum Zitat O’Brien C, Callaghan S, Papaxoinis G, Bennett J, Lee CS, Evans RM (2017) TAS 102 in refractory metastatic colorectal cancer: UK expanded access programme experience. J Clin Oncol 35 (Suppl):e15043 (abstract no. e15043)CrossRef O’Brien C, Callaghan S, Papaxoinis G, Bennett J, Lee CS, Evans RM (2017) TAS 102 in refractory metastatic colorectal cancer: UK expanded access programme experience. J Clin Oncol 35 (Suppl):e15043 (abstract no. e15043)CrossRef
19.
Zurück zum Zitat Sforza V, Martinelli E, Cardone C, Martini G, Napolitano S, Vitiello PP et al (2017) Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open 2(4):e000229CrossRef Sforza V, Martinelli E, Cardone C, Martini G, Napolitano S, Vitiello PP et al (2017) Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open 2(4):e000229CrossRef
20.
Zurück zum Zitat Salvatore L, Niger M, Bellu E, Tamburini E, Garcia-Alfonso P, Amellal N et al (2016) Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview. Ann Oncol 27:149–206 (abstract no. 512P)CrossRef Salvatore L, Niger M, Bellu E, Tamburini E, Garcia-Alfonso P, Amellal N et al (2016) Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview. Ann Oncol 27:149–206 (abstract no. 512P)CrossRef
21.
Zurück zum Zitat Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M et al (2018) The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 90:63–72CrossRef Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M et al (2018) The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 90:63–72CrossRef
22.
Zurück zum Zitat Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312CrossRef Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312CrossRef
23.
Zurück zum Zitat Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T et al (2018) Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum multicenter observational study. Oncologist 23(1):7–15CrossRef Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T et al (2018) Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum multicenter observational study. Oncologist 23(1):7–15CrossRef
Metadaten
Titel
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer
verfasst von
Robert J. Mayer
Howard S. Hochster
Steven J. Cohen
Robert Winkler
Lukas Makris
Axel Grothey
Publikationsdatum
22.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3686-5

Weitere Artikel der Ausgabe 6/2018

Cancer Chemotherapy and Pharmacology 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.